THERIVA BIOLOGICS INC TOVX

Bearish

ASignal's systematic analysis rates TOVX as Bearish.

Reflects the latest available analysis · analyzed Nov 17, 2026

The case on TOVX

Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.

Bull case
  • Oversold RSI at 27.27 indicating potential reversal
  • Gross margin at 100.00% suggesting pricing power or niche product
  • Value score of 0.9 indicating strong valuation metrics
  • Cash position exceeds debt with $8.47M cash vs $3.43M debt
  • Debt-to-equity ratio of 0.32x, indicating low leverage
VS
Bear case
  • Negative MACD histogram and declining momentum
  • Price below both SMA20 and SMA50 indicating downtrend
  • Operating margin at -3265.33% signaling severe operational losses
  • Negative free cash flow of $-7.78M
  • Negative ROE at -99.80% and negative ROA at -19.62%
  • EV/EBITDA at -0.14x suggesting unprofitability
Subscriber-only

See the full verdict on TOVX

ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.

How ASignal analyzes TOVX

Most investors never get a second opinion, let alone several. ASignal runs TOVX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.

The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.

TOVX Stock: Bull vs Bear Case, Bearish Read (Nov 2026)